ACKNOWLEDGMENT
DEL
Novartis donated eltrombopag for evaluation in the trial, and provided partial and unconditional funding to Associazione QOL-ONE. All authors had full and independent access to all the data, and vouch for the accuracy and completeness of the reported data and the fidelity of the trial to the protocol. Editorial assistance in the preparation of this manuscript was provided by Colin Gerard Egan, PhD (CE Medical Writing SRLS, Pisa, Italy), and was funded by Associazione QOL-ONE. Centralized blinded morphology review was performed by Professor Gina Zina of Fondazione Policlinico Universiatario A. Gemelli—Università Cattolica del Sacro Cuore, Italy.See accompanying Editorial, p. 